Human germline biallelic complete NFAT1 deficiency causes the triad of progressive joint contractures, osteochondromas, and susceptibility to B cell malignancy

- Mehul Sharma^{1,2}, Maggie P. Fu^{3,4†}, Henry Y. Lu^{1,2†}, Ashish A. Sharma⁵, Bhavi P. Modi¹, Christina Michalski^{1,2}, Susan Lin¹, Joshua Dalmann¹, Areesha Salman¹, Kate L. Del Bel¹, Meriam Waqas¹, Jefferson Terry⁶, Audi Setiadi⁶, Pascal M. Lavoie^{1,2}, Wyeth W.
 Wasserman^{3,7}, Jill Mwenifumbo³, Michael S. Kobor^{3,4,7}, Anna F. Lee⁶, Anna Lehman³ on behalf of the CAUSES Study, Sylvia Cheng¹, Anthony Cooper⁹, Millan S. Patel³, Stuart E. Turvey^{1,2}
 ¹Department of Pediatrics, BC Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada
- ¹² ²Experimental Medicine Program, Faculty of Medicine, The University of British
- 13 Columbia, British Columbia, Canada
- ¹⁴ ³Department of Medical Genetics, BC Children's Hospital Research Institute, University
- 15 of British Columbia, Vancouver, British Columbia, Canada
- ⁴Genome Science and Technology Program, Faculty of Science, The University of
- 17 British Columbia, Vancouver, British Columbia, Canada
- ⁵Department of Pathology, Emory University, Atlanta, GA, USA
- ¹⁹ ⁶Department of Pathology and Laboratory Medicine, BC Children's Hospital, Vancouver,
- 20 British Columbia, Canada
- ²¹ ⁷Centre for Molecular Medicine and Therapeutics, Vancouver, British Columbia, Canada
- ²² ⁸Department of Orthopaedics, Faculty of Medicine, University of British Columbia
- ²³ [†]These authors contributed equally.
- 24
- 25

26	Correspondence to:	Stuart E. Turvey, MBBS, DPhil, FRCPC
27		BC Children's Hospital
28		950 West 28 th Avenue
29		Vancouver, BC, V5Z 4H4, Canada
30		Phone: 604 875 2345 ext. 5094
31		Email: <u>sturvey@cw.bc.ca</u>
วา		

- 32
- 33 Word Count: 4000
- 34 **Abstract:** 150
- 35

Acknowledgements: This work was supported by grants from the Canadian Institutes 36 of Health Research (PJT 178054) (S.E.T.), Genome British Columbia (SIP007) (S.E.T.), 37 and BC Children's Hospital Foundation. S.E.T. holds a Tier 1 Canada Research Chair in 38 Pediatric Precision Health and the Aubrey J. Tingle Professor of Pediatric Immunology. 39 M.S. is supported by a CIHR Frederick Banting and Charles Best Canada Graduate 40 Scholarships Doctoral Award (CGS-D) and University of British Columbia Four Year 41 42 Doctoral Fellowship (4YF). H.Y.L. is supported by a CGS-D, 4YF, Killam Doctoral Scholarship, Friedman Award for Scholars in Health, and a BC Children's Hospital 43 Research Institute Graduate Studentship. Investigators in the CAUSES Study include: 44 Shelin Adam, Nick Dragojlovic, Christèle du Souich, Alison M. Elliott, Anna Lehman, 45 Larry Lynd, Jill Mwenifumbo, Tanya N. Nelson, Clara van Karnebeek, and Jan M. 46 Friedman. We would like to acknowledge Navdeep Sangha at Thomas Jefferson 47 University Hospital for providing his expertise in B cell lymphomas. We would also like 48 to acknowledge the histology labs at BC Children's Hospital and BC Cancer for their 49 assistance in histological and immunohistochemistry, and the Biomedical Research 50 51 Centre Sequencing Core (BRC-Seq) for their assistance with RNA-Sequencing and processing. 52

54 ABSTRACT

- 55 Discovery of humans with monogenic disorders has a rich history of generating new
- ⁵⁶ insights into biology. Here we report the first human identified with complete deficiency
- of nuclear factor of activated T cells 1 (NFAT1). NFAT1, encoded by *NFATC2*, mediates
- calcium-calcineurin signals that drive cell activation, proliferation, and survival. The
- 59 patient is homozygous for a damaging germline NFATC2 variant
- 60 (c.2023_2026delTACC; p.Tyr675Thrfs*18) and presented with joint contractures,
- osteochondromas, and B cell lymphoma. Absence of NFAT1 protein in chondrocytes
- caused enrichment in pro-survival and inflammatory genes. Systematic single-cell-omic
- analyses revealed an environment that promotes lymphomagenesis with accumulation
- of naïve B cells (with oncogenic signatures *MYC*, *JAK1*), exhausted CD4⁺ T cells,
- ⁶⁵ impaired T follicular helper cells, and aberrant CD8⁺ T cells. This work highlights the
- 66 pleiotropic role of human NFAT1, will empower the diagnosis of additional patients with
- NFAT1 deficiency, and further define detrimental effects a long-term use of calcineurin
- 68 inhibitors.

69 **INTRODUCTION**

Intracellular calcium signaling orchestrates a diverse range of critical physiological and 70 immunological processes, including lymphocyte activation, differentiation, and effector 71 function^{1, 2}. T cell receptor (TCR) or B cell receptor (BCR) engagement activates 72 phospholipase C (PLC), generating inositol-1,4,5-triphosphate (IP3), which, in turn, 73 activates IP3 receptors and creates an influx of Ca²⁺ from the endoplasmic reticulum 74 into the cytosol². Free Ca²⁺ is subsequently bound by calmodulin, resulting in a 75 conformation change that promotes binding of the serine/threonine phosphatase 76 calcineurin^{3, 4}. This calmodulin-calcineurin interaction activates an array of transcription 77 factor families, including the nuclear factor of activated T cells (NFAT) family. This 78 family consists of five members: NFAT1 (NFATc2, NFATp), NFAT2 (NFATc1, NFATc), 79 NFAT3 (NFATc4), NFAT4 (NFATc3, NFATx) and NFAT5⁵, These proteins contain an N-80 terminal transactivation domain (TAD), a regulatory NFAT homology region (NHR), a 81 DNA-binding domain (REL-homology domain, [RHD]) and a carboxy-terminal domain. 82 Activation of NFAT1-4 is dependent on calcineurin-mediated dephosphorylation of the 83 NHR, which exposes a nuclear localization signal and leads to NFAT translocation to be 84

nucleus and transcriptional regulation^{5, 6, 7, 8, 9, 10, 11, 12}.

86 Originally discovered in activated T cells as a protein complex that binds the interleukin-2 (IL-2) promoter¹³, our understanding of the NFAT family has grown remarkably over 87 the past few decades. It is now appreciated that NFATs have a role in the differentiation 88 and activation of many T helper subsets, including T_H1, T_H2, T_H17, T follicular helper 89 cells (T_{FH}), and T regulatory cells (Tregs)^{14, 15}. NFATs are also expressed by and have a 90 function in other immune cells including B cells¹⁶ and dendritic cells¹⁷, as well as in non-91 immune cells, such as cartilage cells^{18, 19, 20}, adipocytes²¹, cardiac cells²² and breast 92 cancer cells²³. Despite our expanded understanding of this transcription factor family, 93 the specific function of each individual NFAT protein has been difficult to define fully due 94 to the redundancy amongst the family members. This is due to highly homologous 95 RHDs, which all bind to a core DNA sequence of (A/T)GGAAA¹¹. On the other hand, 96 their non-redundant roles are attributed to their interaction with other transcription 97 factors via their dissimilar TADs²⁴. Furthermore, NFATs can also alter the function of 98

99 other transcription factors by directly competing for binding sites, as has been reported 100 with nuclear factor kappa B (NF- κ B)²⁵.

A particularly illustrative example of how critical calcineurin and NFATs are in immunity 101 102 and clinical medicine is the fact that calcineurin inhibitors (e.g. cyclosporin A (CsA), tacrolimus [FK506], and pimecrolimus), which suppress T cells without significant 103 104 myelotoxicity, have served as the standard of care over the past 40 years for preventing organ rejection and graft-versus-host disease in transplant recipients^{10, 26, 27, 28}. Further, 105 they have also been used successfully to treat a variety of immune-mediated disorders 106 including atopic dermatitis, psoriasis, rheumatoid arthritis, and uveitis^{28, 29}. However. 107 despite the effectiveness of calcineurin inhibitors, serious adverse side effects have 108 been reported, including nephrotoxicity, lymphomas, and increased susceptibility to 109 infections³⁰. Insight into NFAT biology in humans is thus critical to understand the 110 mechanisms underlying the side-effects of these drugs. 111 One strategy to study human NFAT biology has been to use calcineurin inhibitors³¹. 112 However, since they inhibit all members of the NFAT family, the role of individual 113 members has been challenging to define. Similarly, although targeted genetic disruption 114 115 of individual NFAT family members in mice has helped uncover their specific functions in murine immunity, this approach is not fully transferable to the human system. A 116

powerful complementary approach is to identify and study rare individuals who carry

damaging germline variants in genes encoding members of the NFAT family, allowing

- us to investigate their roles in an unmodified human system. Here, we report the
- identification and characterization of the first human with complete NFAT1 deficiency.

122 METHODS

123 Study participants and consent

All study participants and/or their parents/guardians provided written informed consent to participate. All individuals also provided consent to be published. Research study protocols (H18-02853 and H15-00092) were approved by The University of British Columbia Clinical Research Ethics Board.

128

129 Identification of variant and confirmation by Sanger sequencing

Trio whole exome sequencing (WES) was performed on genomic DNA from the patient 130 and both parents on an Illumina platform at Ambry Genetics (Aliso Viejo, California, 131 USA) after capture of targeted regions using xGen[™] Exome Hybridization Panel (IDT, 132 Coraville, Iowa, USA). More than 99% of targeted regions were covered by at least 10 133 134 reads that averaged 150 bp in length. Reads were aligned to GRCh37/Hg19 and variants were called using BWA-MEM, GATK 3.5-0, SAMtools 0.1.19, and Picard 1.139, 135 and then annotated and prioritized with VarSeg v.1.5 (Golden Helix, Bozeman, 136 Montana, USA). WES data was analyzed using an updated version of our in-house. 137 138 open-source, semi-automated bioinformatics pipeline that has been previously described^{32,} 33 А predicted null NFATC2 variant (c.2023 2026delTACC, 139 140 p.Tyr675Thrfs*18) was selected for further analysis on the basis of: i) the clinical phenotype matching closely to that of *Nfatc2* knockout mice^{18, 34}; ii) the variant resulting 141 in a premature stop codon; and iii) the variant segregating with the disease in the 142 extended family. The variant was confirmed by standard Sanger sequencing of genomic 143 DNA from all individuals of the family. Briefly, genomic DNA was extracted from whole 144 blood (QIAmp DNA Blood Mini Kit; Qiagen, Hilden, Germany) and buccal swabs 145 (DNeasy Blood and Tissue Kit; Qiagen) according to manufacturer's recommendations. 146 The variant region was PCR amplified using GoTaq Green Master Mix (Promega; 147 Madison, Wisconsin, USA) and primers that flank the area: Forward: 148 5'-5'-AACACCCATTAGACAGTGGGC-3' CAGGGACAGGAGTCATCCAC-3'; Reverse: 149

(Integrated DNA Technologies; Coralville, Iowa, USA). The PCR product was purifiedusing a QIAquick PCR Purification Kit (Qiagen) and sequenced using the same primers.

152

153 Cell isolation, culture, and immortalization of lymphoblastoid cell lines (LCLs)

Peripheral blood mononuclear cells (PBMCs) were isolated by standard Ficoll-Paque 154 155 (GE Healthcare, Chicago, Illinois, USA) density centrifugation from four discrete blood 156 draws and time points from the patient over a span of two years, one time point from 157 four heterozygous family members, and from eight unique age-matched healthy controls. PBMCs were cultured in complete RPMI-1640 (GE Healthcare) supplemented 158 159 with 10% heat inactivated FBS (Gibco, Life Technologies; Rockville, Maryland, USA), 2mM L-glutamine (HyClone, Thermo Fisher Scientific; Waltham, Massachusetts, United 160 161 States), and 1mM sodium pyruvate (Gibco, Life Technologies; Carlsbad, California, 162 USA) in the presence or absence of various stimuli described in the following sections.

Lymphoblastoid cell lines (LCLs) were derived by EBV transformation and cultured in

complete RPMI-1640 as previously described by our group^{35, 36}. Briefly, PBMCs from

the patient (II-1), one heterozygous control (II-2), and one healthy control individual

were cultured in complete RPM1-1640 media (GE Healthcare) supplemented with

tacrolimus (AG Scientific, San Diego, California) for 1 h. Cells were then infected with

supernatant from a viral replication-permissive marmoset cell line B95-8 (ATCC,

169 Manassas, Virginia, USA) until sufficient B cell blasts were generated. LCLs were

170 cultured in complete RPMI-1640 media without tacrolimus.

171 Chondrocytes were grown from an osteochondroma that was surgically removed from 172 the patient's proximal tibia. The small cartilage component was excised from connective 173 tissue and placed in separate wells in a 6-well plate and digested with 200 U/ml 174 collagenase in complete Dulbecco's Modified Eagle Medium (DMEM; GE Healthcare) 175 supplemented with 10% heat inactivated FBS (Gibco, Life Technologies, Rockville, Md), 176 2mM L-glutamine (HyClone, Thermo Fisher Scientific), and 1mM sodium pyruvate 177 (Gibco, Life Technologies) and 1x Antibiotic-Antimycotic (Gibco, Thermo Fisher) for 1

day at 37°C. Cells were filtered with a 40µM cell strainer and seeded in a monolayer
 and allowed to adhere.

180

181 Stable expression of NFAT1 using a Lentivirus vector

Stable expression of NFAT1 was established as previously described^{37, 38}. Briefly, the 182 183 NFATC2 (NM_173091) gene was cloned out of a Myc-DDK-tagged NFATC2 plasmid (Cat#: RC213966, OriGene Technologies; Rockville, Maryland, USA) and cloned into a 184 185 GFP-tagged Lenti vector (Cat#: PS100071, OriGene Technologies) using EcoRI-HF (Cat#: R3101) and NotI-HF (Cat#: R3189), both from New England BioLabs (Ipswich, 186 Massachusetts, USA). GFP-tagged NFATC2 and GFP-expressing empty vector (EV) 187 were packaged using 3rd generation packaging plasmids, and transfected into HEK 188 189 293T cells. Culture media was collected, centrifuged, filtered, concentrated, and stored 190 at -80°C before use.

To establish patient-derived chondrocytes that stably express WT NFAT1, chondrocytes 191 were infected with EV or WT NFATC2 lentiviral particles and 5ug/ml polybrene (Sigma-192 Aldrich, St Louis, Mo), cultured, and expanded in high glucose DMEM (HyClone) 193 supplemented with 10% FBS and 2mM ₁-glutamine. Expanded cells were sorted on 194 GFP expression using a BD FACS Aria (BD Biosciences) cell sorter. To establish 195 patient T cells that express WT NFAT1, isolated PBMCs were stimulated with 196 CD3/CD28 T cell activator (Cat#: 10971; Stemcell, Vancouver, Canada) for 3 days, 197 infected with EV or WT NFATC2 particles for 24 hours at 37°C, and stimulated with 198 CD3/CD28 T cell activator for another 3 days before undergoing downstream flow 199 200 cytometric analyses.

201

202 Cytometric Bead Array (CBA)

A cytokine bead array was used to measure cytokine production in chondrocytes as
 previously described³⁹. Briefly, patient and WT-*NFATC2*-transduced chondrocytes were
 seeded in T25 flasks in complete DMEM media (GE Healthcare) without antibiotics and

allowed to reach confluency. Chondrocytes were washed and subsequently left

207 untreated in media alone or stimulated with 50ng/mL phorbol 12-myristate 13-acetate

208 (PMA) (Sigma) and 1µM ionomycin (Sigma) (P/I) or 20ng/mL IL-1β (Cat#: 14-8018-62;

eBiosciences, San Diego, California, USA) at 37°C for 24h. Supernatants were

collected and a human inflammatory cytokine CBA kit was used to measure the

concentration of IL-6 (BD Biosciences, Cat#: 552932; Franklin Lakes, New Jersey,

- USA) according to manufacturer's recommendations⁴⁰. Samples were acquired using a
- BD LSRII flow cytometer and analyzed using FlowJo (BD Biosciences).
- 214

215 Immunoblotting

216 Changes in NFAT1 expression and phosphorylation status was detected by stimulating LCLs with 10µM ionomycin for 10 min in complete RPMI or empty vector (EV)- or WT-217 NFATC2-transduced chondrocytes with P/I or 20ng/mL IL-1 β for 15 min in complete 218 DMEM at 37°C. Whole cell lysates were prepared by lysing untreated and stimulated 219 220 LCLs or chondrocytes in a modified radio immunoprecipitation assay buffer with the Halt 221 protease and phosphatase inhibitors cocktail (Thermo Fisher Scientific). Lysates were separated by 10% SDS-PAGE and transferred onto polyvinylidene difluoride 222 223 membranes (Immobilon-FL; MilliporeSigma. Billerica. Massachusetts. USA). Membranes were blocked with 5% BSA in Tris-buffered saline with Tween-20, 224 225 incubated with primary antibodies for 18h at 4°C, incubated with secondary antibodies 226 for 1h at room temperature, and imaged using a LI-COR Odyssey infrared scanner (LI-227 COR Biosciences, Lincoln, Nebraska, USA). The primary antibodies used were the following: NFAT1 (Cat#: 4389) and β -actin (Cat#: 3700) both from Cell Signaling 228 Technologies (Danvers, Massachusetts, USA). The secondary antibodies used were 229 the following: goat anti-rabbit IgG DyLight 800 conjugated (611-145-002-0.5; Rockland 230 231 Immunochemicals, Pottstown, Pennsylvania, USA) and goat anti-mouse IgG IRDye 680RD (926-6870; LI-COR). 232

233

234 Quantification of *NFATC2* transcript abundance by quantitative PCR (qPCR)

qPCR was conducted as previously described³⁵. Briefly, total RNA was extracted from

- unstimulated or 18h ionomycin-stimulated LCLs using a RNeasy Plus Mini Kit (Qiagen)
- and converted to cDNA using an iScript cDNA synthesis kit (BioRad Laboratories;
- Hercules, California, USA). Transcript abundance was measured using a Universal
- 239 SYBR Green Super Mix (Bio-Rad) and a 7300 Real-Time PCR System (Applied
- Biosystems, Foster City, California, USA). The primers used for *NFATC2* were the
- 241 following: Forward: 5'-GTCAGCCTCAGCACTTTACC-3'; Reverse: 5'-
- 242 ATCAGAGTGGGGTCATATTCATC -3' (PrimeTime; Integrated DNA Technologies).
- Relative transcript abundance was quantified relative to ACTB using the $2^{-\Delta\Delta CT}$
- 244 method⁴¹.
- 245

246 **RNA-Sequencing**

247 To investigate the global transcriptome, EV- or WT-*NFATC2*-transduced chondrocytes were unstimulated, 4h P/I-stimulated, or 4h 20ng/mL IL-1β-simulated. RNA was 248 extracted in triplicate as previously described³⁵ using a RNeasy Mini Plus Kit (Qiagen) 249 according to manufacturer's recommendations. RNA was prepared following the 250 251 standard protocol for the NEBNext Ultra II Stranded mRNA (New England Biolabs) and sequenced on the Illumina NextSeq 500 with Paired End 42 bp x 42 bp reads. De-252 multiplexed read sequences were aligned to a reference sequence using Spliced 253 254 Transcripts Alignment to a Reference (STAR) aligner. E1 Assembly and expression were estimated using Cufflinks E2 through bioinformatics apps on Illumina BaseSpace. 255

Expression data were normalized to reads between samples using the edgeR package 256 in R (R Foundation, Vienna, Austria). Normalized counts were filtered to remove low 257 counts using the filterByExpr function in edgeR⁴². Batch correction and differential 258 expression was conducted using Limma⁴³. Pathway analysis was done by first 259 performing Gene Set Enrichment Analysis (GSEA) with 1000 permutations using the 260 Molecular Signatures Database Hallmark module. Signal-to-noise ratio was used for 261 gene ranking and the obtained NESs and P-values were further adjusted using the 262 263 Benjamini-Hochberg method. Pathways with an adjusted P-value < 0.05 were 264 considered significant. Leading edge genes from significant pathways between EV and 265 WT-*NFATC2*-transduced chondrocytes were identified. Expression levels of these 266 genes were then determined in each group.

267 Sample level enrichment analyses (SLEA) scores were computed as previously

described⁴⁴. Briefly, z-scores were computed for gene sets of interest for each sample.

269 The mean expression levels of significant genes were compared to the expression of

- 1000 random gene sets of the same size. The difference between observed and
- 271 expected mean expression was then calculated and represented on heatmaps
- 272 generated using Morpheus (https://software.broadinstitute.org/morpheus). Raw data are
- 273 deposited on Gene Expression Omnibus at the following accession number
- 274 GSE193414.
- 275

276 Single Cell RNA-Sequencing

Targeted single cell RNA-Sequencing of 500 curated immune-related genes was 277 conducted on PBMCs from the patient, three heterozygous controls, and two age-278 279 matched healthy controls using the BD Rhapsody Single Cell platform, the Rhapsody Cartridge Reagent Kit (BD, Cat#: 633731), the BD Rhapsody Cartridge Kit (BD, Cat#: 280 633733), the Rhapsody cDNA Kit (BD, Cat#: 633733), the Rhapsody Targeted mRNA 281 amplification Kit (Cat#: 633774), and the Human Single-Cell Multiplexing Kit (BD, Cat#: 282 283 633781) according to manufacturer's recommendations. Briefly, thawed PBMCs were rested overnight and stimulated with P/I or left untreated for 4h. Cells from each donor 284 285 were labelled with sample tags, washed with stain buffer and pooled together in cold sample buffer to obtain ~25,000 cells in 620ul for each of the unstimulated and 286 287 stimulated samples. Two nanowell cartridges were primed and subsequently loaded with the pooled samples for 15min at room temperature on the Rhapsody Express 288 instrument (BD, Cat#: 633702). Cell capture beads were prepared and loaded onto the 289 cartridge. The cartridge was washed, cells were lysed, and beads were retrieved. The 290 291 sample then underwent reverse transcription and exonuclease I treatment. cDNA was 292 amplified using a custom immune panel (**Supp. Table 5**) via PCR. mRNA PCR products 293 were separated from sample tag products with double-sided size selection using AMPure beads (Beckman Coulter, Cat#: A63880). Separated products were further 294

295 amplified by PCR and then purified using AMPure beads. Product quality was checked using Agilent DNA High Sensitivity Kit (Agilent Technologies, Cat#: 5067-4626) on the 296 297 Agilent 2100 Bioanalyzer (Agilent Technologies, Cat#: G2940CA). PCR products were then PCR amplified using two index primers, one for unstimulated (5'-CGAGGCTG-3') 298 299 and one for stimulated (5'-AAGAGGCA-3') samples. Indexed products were again purified using AMPure beads and sample quality was checked using the Agilent 2100 300 301 Bioanalyzer. Libraries were diluted to 650pM and multiplexed for paired-end (2 x 115bp) sequencing on a NextSeq2000 Sequencing System (Illumina) at 200 cycles P3 for 1.1 302

303 billion reads.

304 FASTQ files were processed using the BD Rhapsody Targeted Analysis Pipeline and

305 Seven Bridges (www.sevenbridges.com) according to manufacturer's

recommendations. Briefly, R1 and R2 reads were filtered based on read length, quality,

and highest single nucleotide frequency. R1 reads are annotated to identify cell labels,

unique molecular identifiers (UMI), and filtered for >6 Poly(T) tail. Bowtie2 version 2.2.9

was used to map the R2 reads to the reference sequences. All reads, R1 and R2, with

the same cell label, UMI sequence, and gene were collapsed into a single molecule.

Recursive substation error correction (RSEC) and distribution-based error correction

(DBEC) were used to adjust for PCR errors in UMI sequences (which can give rise to

artifacts). Putative cells were determined by considering all reads associated with

314 DBEC-adjusted molecules. The minimum second derivative along the cumulative reads

curve is identified as the inflexion point, after which the cells are labelled as noise.

Filtered putative reads that align to a sample tag sequence were used to identify sample

labels for a cell. Finally, labelled DBEC-adjusted molecule counts were obtained in a

318 CSV format for downstream analyses.

The R package Seurat⁴⁵ was utilized for all downstream analysis. No gene per cell cutoffs were imposed since we were using a targeted 500-gene panel. Scaling and clustering was performed on each pool of samples independently. Dimensionality

reduction using PCA was based on all 500 genes and UMAP was based on the first 20

PCs. Cell identities were first annotated with SingleR using fine labeling from the

Novershtern hematopoietic dataset^{46, 47}. The annotation was refined manually based on

the UMAP clustering patterns, grouping the SingleR labels into 8 main populations: 325 Naïve B cells, Memory B cells, Naïve CD4⁺, Memory CD4⁺, Memory CD8⁺, Monocytes, 326 327 NK cells, and undefined. For differential gene expression analyses, we utilized the Seurat implementation of negative binomial test, assuming an underlying negative 328 329 binomial distribution in RNA-Seg data while leveraging the UMI counts to remove technical noise^{48, 49}. Raw data are deposited on Gene Expression Omnibus at the 330 331 following accession number GSE193410. All downstream analysis scripts used in analysis are available on GitHub (https://github.com/maggie-fu/NFATC2 RNAseg/). 332

333

334 Lactate Dehydrogenase (LDH) Assay

Chondrocyte resistance to cell death was quantified using a lactate dehydrogenase 335 336 assay (LDH) according to manufacturer's instructions (Promega, Cat#: G1780). Briefly, 337 EV- or WT-NFATC2-transduced chondrocytes were seeded in 96-well plates at a concentration of 5000 cells/well. Cells were rested until they reached confluency and 338 subsequently stimulated with P/I over a time course, including 0, 2, 4, 6, 8, 10, and 12 339 days at 37°C. 50 µl of cell supernatants were collected, added to 50µl of CytoTox96 340 341 reagent, and incubated in the dark for 30 min at room temperature. The reaction was subsequently stopped with 50µl of stop solution. Maximum LDH release was measured 342 at each time point by lysing cells. Absorbance was measured on the Infinite M200 plate 343 reader (Tecan; Männedorf, Switzerland) at 492nm. Cell death was defined as a 344 percentage of maximum LDH release. 345

346

347 **B cell expansion and differentiation**

Naïve B cells were isolated from PBMCs of the patient, one heterozygous family
member and 6 healthy controls using the EasySep Human Naïve B Cell Isolation Kit
(Cat#: 17254; Stemcell) according to manufacturer's recommendations. Cells were
stained with the 'Plasmablast Differentiation' panel (**Supp. Table 6**) described in the
'Flow Cytometry' section before and after stimulation with ImmunoCult-ACF Human B

Cell Expansion Supplement (Cat#: 10974; Stemcell) for 6 days in order to determine the
 proportion of different subsets by flow cytometry.

355

356 Clinical-Grade Flow Cytometry

Patient clinical immunophenotyping was also carried out at an accredited clinical flow 357 358 cytometry laboratory. Whole blood was collected and stained using DURAClone tubes 359 (Beckman Coulter; Brea, California, USA) according to the manufacturer's 360 recommendation. Briefly, fresh blood was incubated with dried reagent tubes and incubated in the dark at room temperature for 15 min. Cells were washed in 3mL of PBS 361 2 times, before being fixed in 500uL of PBS containing 0.1% formaldehyde and 362 subsequently acquired. Panels focused on the analysis of T cell subsets (DURAClone 363 364 IM T Cell Subsets, Beckman Coulter; Cat#: B53328) and B cell subset (DURAClone IM 365 B Cell, Beckman Coulter; Cat#: B53318). All flow data were acquired on a Navios flow cytometer and then analyzed using Kaluza software (Beckman Coulter). 366

367

368 **Research-Grade Flow Cytometry**

To carry out immunophenotyping and intracellular cytokine detection, PBMCs from the 369 patient, heterozygous family members, and age-matched controls were stimulated with 370 371 P/I for 4h at 37°C in the presence of GolgiStop (Cat# 554724, BD Biosciences). Following stimulation, cells were stained with a cocktail of antibodies against surface 372 markers for 20 min on ice then fixed with the Foxp3 Fixation/Permeabilization working 373 374 solution (Cat#: 00-5123-43; Invitrogen, Thermo Fischer Scientific) from the eBioscience 375 Foxp3 Transcription Factor Staining Buffer Set (Cat# 00-5523-00, Invitrogen, Thermo Fisher Scientific) for 20 min. Fixed cells were then stained with antibodies directed 376 against intracellular cytokines or transcription factors for 45 min in 1x Permeabilization 377 Buffer (Cat#: 00-8333-56: Invitrogen, Thermo Fischer Scientific). Samples were then 378 379 washed and analyzed on the BD FACSymphony flow cytometer (BD Biosciences). Data were analyzed using FlowJo software (BD Biosciences). Antibody panels used for 380 staining are listed in Supp. Table 6. 381

382

383 Histology

Formalin-fixed, paraffin-embedded lymph node tissue was sectioned at 4μM and
subjected to routine hematoxylin and eosin (H&E) staining or immunohistochemistry
(IHC). The following IHC antibodies were used: CD21 (IF8, Dako), CD20 (L26,
Ventana), BCL6 (P6-B6P, Dako), CD30 (Ber-H2, Ventana), and BCL2 (124, Dako).
CD21, BCL6, and BCL2 IHC were performed on the Dako Autostainer. CD20 and CD30
IHC were performed on the Dako Omnis Automated Slide Stainer.

390

392 **RESULTS**

393 Clinical features of complete human NFAT1 deficiency

The patient (designated II-1 on the family pedigree) is born to consanguineous parents. 394 395 After a healthy birth, the patient started developing difficulty bending his knees with no associated swelling, pain, erythema, or morning stiffness in early childhood (ages 0-5 396 397 years). Insidiously, many joints developed a similar painless decreased range of motion 398 causing difficulty with ambulation. Medical care was disjointed until the patient was in 399 his teenage years (ages 15-20 years). Assessment then demonstrated a 400 neurodevelopmentally normal young man with marked bilateral fixed flexion 401 contractures of knees, hips, and ankles. Multiple upper limb joints also demonstrated 402 reduced range of motion, including wrists, hands, and shoulders (Fig. 1A, Table 1). 403 Muscle strength and deep tendon reflexes were all intact. The joint changes significantly impacted his gait, causing him to walk with an increased anterior pelvic tilt, and leading 404 405 to decreased dynamic hip range of motion with particularly diminished extension through mid to late stance. He also had diminished dynamic knee range of motion with 406 knee flexion throughout stance and swing and mild equinus bilaterally at his ankles 407 (Supp. Table 1). He had absent distal digital creases and prominent fetal fat pads on all 408 fingers. Echocardiography showed a mildly hypertrophied left ventricle with multiple 409 410 cords and an appearance of coarse trabeculae on the septal and free wall surfaces. 411 Dual-energy X-ray absorptiometry (DEXA) scanning revealed low total body bone mineral density (0.888 g/cm², z-score for chronologic age being -1.9 [-0.4 after adjusting 412 for height]). X-rays showed flattening of multiple lower thoracic and lumbar vertebral 413 414 bodies suggesting mild vertebral compression fractures. Two 415 osteochondromas/exostoses were also identified; one on the medial aspect of the right 416 proximal tibial metaphysis (2cm) and a second on the anterior aspect of the right proximal fibula (3cm) (Fig. 1A, 1B). In summary, the main musculoskeletal findings are 417 contractures of the large and small joints of the upper and lower limbs. 418 419 osteochondromas, and osteopenia (Table 1).

In his late teens (ages 15-20 years), the patient presented with abdominal pain, fever,
 night sweats and weight loss (i.e. B symptoms) and was ultimately diagnosed B-cell

422 lymphoma, unclassifiable, with features intermediate between diffuse large B-cell

- 423 lymphoma (DLBCL) and classic Hodgkin lymphoma (cHL). Lymphoid tissue biopsy
- 424 showed effacement of typical node architecture and the absence of clear germinal
- 425 centers and follicular structure. There was a prominent population of larger atypical
- ⁴²⁶ lymphocytes (CD79a⁺CD30⁺CD20⁺CD15⁻BCL6⁺) in the background of mature CD4⁺ and
- 427 CD8⁺ T cells (**Fig. 1C**). He was staged as Ann Arbor stage 4B with widespread disease,
- 428 including abdominal, inguinal, hepatic, splenic, paratracheal, and subcarinal
- 429 lymphadenopathy. The patient was treated with 6 cycles of a modified dose-adjusted
- 430 EPOCH-R regimen without vincristine and went into full remission.
- 431

Whole-exome sequencing (WES) reveals a novel damaging homozygous variant in *NFATC2*

434 Given the unique phenotype of the patient, consanguinity, and significant family history, we performed whole exome sequencing (WES) to identify a potential genetic etiology. 435 The patient was found to carry a previously unreported homozygous 4-base pair 436 deletion in exon 8 of the gene nuclear factor of activated T cells 2 (NFATC2) encoding 437 438 the NFAT1 transcription factor. This variant causes a frameshift leading to a premature codon (NM 173091:c.2023 2026delTACC; NP 775114:p.Tyr675Thrfs*18). 439 stop Sanger sequencing of the variant region in whole blood confirmed that it segregated 440 with disease within the patient family (Fig. 1D, 1E). The variant localizes to the DNA 441 binding domain of the NFAT1 protein and affects an evolutionarily conserved region 442 (Fig. 1F). 443

444 This variant led to significantly reduced NFATC2 transcript abundance in patient-derived lymphoblastoid cell lines (LCLs) when compared to heterozygous control- and unrelated 445 446 control-derived LCLs (Fig. 1G). To investigate the impact on NFAT1 protein function, we measured NFAT1 expression in LCLs pre- and post-stimulation with the NFAT1 447 448 activator, ionomycin (Fig. 1H), and in the absence or presence of the calcineurin inhibitor tacrolimus (FK506). We confirmed that NFAT1 expression was undetectable in 449 450 patient LCLs, but reduced in heterozygous control LCLs (Fig. 11). Furthermore, NFAT1 was strongly dephosphorylated in both wild-type and heterozygous control LCLs 451

following ionomycin stimulation and this effect was effectively inhibited by FK506
 treatment (Fig. 1G, 1I).

454

455 NFAT1-deficient patient chondrocytes are more enriched in cell proliferation and 456 inflammatory genes with elevated IL-6 production and resistance to cell death

457 Informed by the patient's joint contractures and osteochondromas, we assessed the impact of NFAT1 deficiency on chondrocytes isolated from the excised tibial 458 459 osteochondroma. Patient chondrocytes had undetectable NFAT1 expression (Fig. 2A). To study the impact of NFAT1 deficiency on chondrocytes, we engineered a WT 460 NFATC2 lentivirus construct and transduced patient chondrocytes to rescue NFAT1 461 expression. This restored function to the pathway as demonstrated by NFAT1 462 463 dephosphorylation that was sensitive to FK506 inhibition (Fig. 2A). Further, treatment with IL-1β, a key cytokine involved in cartilage damage in arthritis⁵⁰, did not change 464 NFAT1 phosphorylation status. 465

To define the impact of NFAT1 deficiency on the global transcriptome of chondrocytes, 466 467 we conducted bulk RNA-Seq on empty vector (EV) or WT NFATC2 -transduced patient 468 chondrocytes untreated or stimulated with P/I or IL-1 β . We identified 187 significantly upregulated and 146 significantly downregulated genes between P/I-stimulated WT 469 NFATC2- and EV-transduced chondrocytes, which may represent NFAT1 suppressed 470 and enhanced genes, respectively (Fig. 2B, 2C). Gene set enrichment analysis (GSEA) 471 identified significant enrichment in pathways involved with cellular growth and 472 inflammation (Fig. 2D). Notable was the enrichment of cell proliferation pathways both 473 at baseline and in response to P/I stimulation in NFAT1-deficient EV-transduced 474 chondrocytes, including G2/M Checkpoint (unstimulated: NES=1.790, FDR<0.001; P/I 475 stimulated: NES=1.544, FDR=0.047) and E2F targets (unstimulated: NES=1.704, 476 FDR=0.004; stimulated: NES=1.667, FDR=0.013) (Fig. 2D). To assess the functional 477 consequences of these transcriptomic findings, we stimulated EV- and WT NFATC2-478 transduced chondrocytes over a time course up to 12 days with P/I and monitored cell 479 survival. Here, we discovered that EV-transduced NFAT1-deficient chondrocytes were 480

481 significantly more resistant to cell death than WT *NFATC2*-transduced chondrocytes

482 (**Fig. 2E**).

The IL-6-JAK-STAT3 signaling pathway was also significantly enriched in unstimulated EV-transduced NFAT1-deficient chondrocytes (NES=1.543, FDR=0.035) (Fig. 2D). Confirming this at the protein level, both unstimulated and P/I-stimulated EV-transduced NFAT1-deficient chondrocytes produced significantly more IL-6 than 'rescued' WTtransduced chondrocytes (Fig. 2F). Taken together, these findings suggest that NFAT1 regulates chondrocyte growth, death, and proinflammatory transcriptional programs, collectively leading to aberrant connective tissue homeostasis.

490

491 **NFAT1 deficient B cells are largely naïve ex vivo and express proliferation**

492 markers

Given that NFAT1 is expressed in most lymphocytes¹⁶, we conducted targeted single

cell RNA-Sequencing (scRNA-Seq) on patient PBMCs alongside 5 healthy controls (2

age-matched sex-matched healthy controls and 3 heterozygous family members)

496 stimulated with P/I to identify cell type-specific defects. Unsupervised clustering analysis

⁴⁹⁷ revealed markedly reduced memory B cells and elevated memory CD4⁺ T cells in the

498 patient PBMCs (**Fig. 3A**).

499 Since patient B cells were largely naïve, we focused our differential gene expression

500 (DE) analysis on patient and control naïve B cells (Fig. 3B). We discovered significantly

501 increased transcript abundance of pro-survival, proliferation, and anti-apoptotic genes

502 frequently associated with lymphoma in patient cells compared to controls. This

503 includes MYC^{51} , $HIF1A^{52}$, JAK1, $STAT3^{53}$, $TNFAIP8^{54}$, and $PIK3AP1^{55}$ (Fig. 3C).

504 Consistent with the documented NFAT1 deficiency, classical NFAT1 targets such as

505 TNF and $LTA^{56, 57}$ were significantly decreased in patient naïve B cells.

To study this B cell phenotype further, we carried out multi-parameter flow cytometric analyses on PBMCs from the patient, 4 heterozygous healthy family member, and 8 healthy controls (see **Supp. Fig. 1A** for gating strategy). Direct detection of NFAT1 protein confirmed the lack of NFAT1 in patient B cells as compared to controls (**Fig.**

3D). Validating our scRNA-Seq data, and consistent with clinical-grade flow cytometry (**Supp. Table 2**), patient B cells showed signs of a developmental arrest, with significantly elevated transitional B cells (**Fig. 3E, 3F**) and naïve B cells (**Fig. 3G, 3I**) with a concurrent reduction in class-switched memory B cells (**Fig. 3G, 3H**). Interestingly, despite the reduced frequency of memory B cells in the patient, plasmablast numbers were comparable to controls (**Fig. 3J**) (**Supp. Fig. 1A**), perhaps explaining the patient's normal serum immunoglobulin levels.

517 Expanding our naïve B cell analyses further, we observed markedly elevated IgD

expression (Fig. 3K) (Supp. Fig. 1B) and generally comparable to control IgM

expression (**Fig. 3K**) (**Supp. Fig. 1C**) in patient naïve B cells. These IgD^{hi} naïve B cells

were characterized by elevated expression of the cell proliferation marker Ki67 (Fig. 3L,

521 **3M**), but significantly reduced TNF- α expression (**Fig. 3N, 3O**) which was consistent

522 with the scRNA-Seq data.

Given the striking B cell differentiation defect in the patient, we next asked whether this was intrinsic or extrinsic to B cells. We isolated naïve B cells from the patient and controls and quantified the frequency of class-switched memory B cells and plasmablasts before and after treatment with an *in vitro* B cell activation and expansion cocktail. We demonstrated intact differentiation of both memory B cells (**Fig. 3P**) (**Supp. Fig. 1D**) and plasmablasts (**Fig. 3P, 3Q**), suggesting that the differentiation defect is likely to be extrinsic to B cells.

530

531 **NFAT1 deficient CD8⁺ T cells show impaired polyfunctionality**

Since both NFAT1 deficiency and calcineurin inhibitor treatment are known to suppress
CD8⁺ T cell effector function^{58, 59} and suppressed CD8⁺ T cells can create conditions
that favour lymphomagenesis⁶⁰, we next analyzed CD8⁺ T cell differentiation and
function by scRNA-Seq and flow cytometry. DE analysis of patient memory CD8⁺ T cells
revealed a mixed effector function defect, including decreased transcript abundance of *TNF*, *IFNG*, and *FASLG*, but increased *GZMH*, *GNLY*, and *PFN1* (Fig. 4A, 4B). Flow
cytometric analysis of CD8⁺ T cell subsets revealed no differences in patient naïve and

539 memory populations when compared to controls (Fig. 4C, 4D). However, whereas control CD8 populations expressed easily detectable levels of NFAT1 protein, patient 540 541 CD8 populations were NFAT1-deficient (Fig. 4E). In line with the abnormal effector marker profile in scRNA-Seq, patient CD8⁺ memory T cells showed significantly 542 543 impaired expression of TNF-α and IFN-y expression in response to stimulation (Fig. 4F-**4H**). In contrast, IL-2 expression was intact in both patient naïve and memory CD8⁺ T 544 545 cells (**Supp. Fig. 2A-D**). Patient CD8⁺ memory T cells also exhibited abnormal expression of activation markers, including comparable to control expression of CD40L 546 (Supp. Fig. 2E-F) and PD-1 (Fig. 4I) (Supp. Fig. 2H), but elevated CD69 (Fig. 4I) 547 (Supp. Fig. 2G). These findings indicate a pleiotropic function for NFAT1 in human 548

- 549 CD8⁺ T cells.
- 550

551 **NFAT1 deficiency causes an accumulation of non-functional memory CD4⁺ T cells**

552 The role of NFAT1 in CD4 cell functionality and differentiation is well characterized in

553 mouse studies¹⁴. We sought to see if this held true in human complete NFAT1

⁵⁵⁴ deficiency. scRNA-Seq revealed a marked increase in the memory CD4⁺ T cell

compartment (**Fig. 3A**). We conducted DE analysis on these cells and found

significantly impaired expression of many makers for T helper function (i.e. *TNF* and

557 *CD40LG*) and cell proliferation (i.e. *MYC*) (**Fig. 5A, 5B**). In addition, we observed

increased expression of other activation/exhaustion-related genes such as *TIGIT*,

559 S100A10 and TNFRSF4 (Fig. 5A, 5B). Interestingly, many regulatory components of

the NF-κB pathway (*NFKBIZ*, *NFKBIA*, *REL*) and AP-1 pathway (*FOS* and *JUN*)

showed impaired expression in NFAT1 deficient cells (Fig. 5A, 5B), highlighting the

562 broad defects associated with human NFAT1 deficiency.

We next examined the impact of NFAT1 deficiency on CD4⁺ T cell differentiation by flow cytometry. Confirming our scRNA-Seq data, the patient possessed decreased naïve CD4⁺ T cells with a concurrent increase in CD4⁺ central memory T cells (**Fig. 5C, 5D, Supp. Table 2**) and both these subsets had undetectable levels of NFAT1 protein, in contrast to controls (**Fig. 5E**). Within the memory CD4⁺ T cell compartment, the patient had significantly decreased T_H1, T_H2, T_H17 and T_{FH} cells as measured by cytokine (i.e.

⁵⁶⁹ IFN-γ, IL-4, IL-17A and IL-21) production (**Fig. 5F–5K**). Furthermore, classical NFAT1 ⁵⁷⁰ targets IL-2 and TNF- α^7 , were significantly reduced in patient memory CD4⁺ T cells ⁵⁷¹ (**Fig. 5L, 5M**). In contrast, naïve CD4⁺ T cells did not exhibit any significant differences ⁵⁷² in the expression of these same cytokines (**Supp. Fig. 3A-3I**).

573

574 Human NFAT1 deficiency does not cause any overt defects in Tregs

Since NFAT1 was shown to be critical for controlling Treg suppressive function in 575 mouse models⁶¹, we studied whether Treg development and/or function was affected in 576 NFAT1 deficiency. Surprisingly, we found normal frequencies of Tregs and their naïve 577 578 and activated subsets (Supp. Fig. 5A-5C). From a functional standpoint, activated patient Tregs showed significantly reduced TNF- α (**Supp. Fig. 5D-5E**), but normal IFN- γ 579 (Supp. Fig. 5D-5E) and IL-2 (Supp. Fig. 5G-5H) expression. Similarly, Treg markers of 580 stability and activation were largely normal, including FOXP3, Helios, CD25, CD69, 581 582 CTLA4, and ICOS (Supp. Fig. 5I-5N), except for PD-1, which was significantly elevated (Supp. Fig. 50). 583

584

585 NFAT1 deficiency impairs T_{FH} function

Given the impaired production of a variety of T cell cytokines (**Fig. 5F-5N**) by CD4⁺ memory T cells, we asked whether the expression of activation markers and critical T cell coreceptors by this T cell population is affected by NFAT1 deficiency. Here we found significantly increased CD69, PD-1, and ICOS, but decreased CD25 and CD40L after P/I treatment (**Fig. 6A**) (**Supp. Fig. 3P-3T**). A similar profile was observed in naïve CD4⁺ T cells (**Supp. Fig. 3K-5O**).

Reduced CD4⁺ memory T cell activation marker expression and cytokine secretion paired with an extrinsic B cell differentiation defect prompted us to assess frequency and function of circulating T_{FH} cells in the patient (**Supp. Fig. 4A**). Confirming cytokine staining (**Fig. 5F-5K**), T_{FH} numbers were comparable to controls (**Fig. 6B, 6C**). Despite this, the expression of CD40L and IL-21, both important for B cell activation and

- 597 differentiation⁶², was markedly impaired (**Fig. 6D-6F**). Importantly, these defects were 598 reversed when we transduced patient CD4⁺ T cells with WT *NFATC2*, which restored 599 CD40L and TNF- α expression to a level that was comparable to healthy controls (**Fig.** 600 **6G-6I**).
- 601
- 602

603 **DISCUSSION**

Here we present a comprehensive clinical, immunological, biochemical, and 604 transcriptional workup of the first reported case of human complete NFAT1 deficiency in 605 a young man with a clinical triad of: progressive joint contractures, osteochondromas, 606 607 and B cell malignancy. Based on our study, patients should be worked up for possible NFAT1 deficiency if they present with this triad of features. Although the full phenotype 608 of human NFAT1 deficiency will only be appreciated when more affected individuals are 609 identified, other clinical flags include: i) impaired B cell development (increased naïve, 610 decreased memory); ii) normal CD8⁺ T cell development but impaired TNF- α and IFN- γ 611 production and elevated CD69 expression; and iii) increased CD4⁺ memory proportions 612 with reduced T_H subsets and cytokine secretion, and increased CD69, PD-1, ICOS 613 expression. Notably, haploinsufficiency (at least with this particular null variant) was not 614 observed as all heterozygous family members were healthy and unaffected. 615 Studying *Nfatc2^{-/-}* mice has been extremely informative in defining the physiological 616 functions of NFAT1. This includes regulation of chondrogenesis¹⁸ and bone 617 development^{19, 63}, maintenance of steady state hematopoiesis⁶³, suppression and 618 regulation of T cells^{64, 65}, and B cell lymphomagenesis³⁴. Reassuringly, human NFAT1 619 deficiency recapitulates a variety of the features seen in the knockout mice (Table 2). 620 The joint contractures and progressive difficulty in ambulation observed in our NFAT1-621 deficient patient were accurately predicted by *Nfatc2^{-/-}* mice, as was the with excess 622 differentiation, proliferation, and endochondral ossification affecting cartilage cells¹⁸. The 623 pro-growth, pro-survival, and proinflammatory phenotype of patient chondrocytes (Fig. 624 2) suggests that human NFAT1 serves as a repressor of cartilage cell growth and 625 differentiation. Future work will focus on studying how osteopenia arises in the context 626 627 of human NFAT1 deficiency and the contributions of different mesenchymal cells to the patient's musculoskeletal phenotype. Interestingly, bone fractures and osteopenia have 628 also been observed in *Nfatc2^{-/-}* or tacrolimus-treated mice¹⁹, and organ transplant 629 recipients on immunosuppressive regimens that include glucocorticoids and 630 tacrolimus⁶⁶, further strengthening the link to NFAT1 function. In light of these 631 observations, it is important to consider other findings in *Nfatc2^{-/-}* mice, notably the 632

development of chondrosarcomas¹⁸ and susceptibility to osteoarthiritis²⁰, as additional
 patients with NFAT1 deficiency are identified.

One of the most significant phenotypes in our patient was the development of a rare 635 mature B cell lymphoma characterized by large CD20⁺CD30⁺CD15⁻BCL6⁺ cells (Fig. 636 637 **1C**). Intriguingly, an increased incidence of anaplastic and/or plasmablastic plasmacytomas –also rare– was also observed with aging *Nfatc2^{-/-}* mice³⁴. Abrogation 638 of NFAT1 function in B cells may confer an intrinsic pro-survival transcriptional program. 639 NFAT1 is critical for repressing cell cycle progression through cyclin E (CCNE2)⁶⁷ and 640 our findings extend this understanding to suggest that JNK signaling (via DUSP4⁶⁸) and 641 AKT signaling (via *PIK3AP1*⁵⁵) (**Fig. 3B, 3C**), might contribute to dysregulated B cell 642 proliferation in the context of NFAT1 deficiency. In parallel, the CD4⁺ T cells of the 643 NFAT1-deficient patient expressed high levels of the inhibitory checkpoint marker, PD-1 644 (Fig. 6A), which has frequently been associated with B cell lymphomas^{69, 70}. This could 645 inhibit effective anti-tumour effector functions in the patient. This is likely further 646 exacerbated by the markedly reduced production of effector cytokines (TNF- α , IFN-y) in 647 patient's CD4⁺ and CD8⁺ T cells (**Fig. 4-5**). Together these data indicate that ongoing 648 clinical tumor surveillance, and a heightened awareness of tumor risk, will be an 649 650 important aspect of the long-term care of patients with NFAT1 deficiency.

Studying complete human germline NFAT1 deficiency can provide new insights into the 651 652 use of calcineurin inhibitors and improves our understanding of the consequences of long-term NFAT1 inhibition by calcineurin inhibitors (**Table 2**). Patients undergoing solid 653 organ or allogeneic hematopoietic stem cell transplantation are frequently treated with 654 an immunosuppressive regimen including a calcineurin inhibitor for extended periods of 655 656 time. This can lead to a rare complication called post-transplant lymphoproliferative disorder (PTLD). Most PTLD's are a B cell proliferative disorder believed to be due to 657 impaired CD8⁺ T cell function and EBV infection^{71,72}. Our findings complement this 658 understanding since NFAT1-deficient CD8⁺ T cells express significantly reduced 659 660 cytotoxic mediators such as FASLG and IFNG (Fig. 4B, 4H). Consistent with NFAT1dependent regulation of the transcription factor Eqr3 being critical for FasL induction⁷³, 661 we found that both *EGR3* and *FASLG* were downregulated in CD4⁺ and CD8⁺ patient 662

memory T cells (Fig. 4-5). Future work should focus on the role of NFAT1 in intrinsic B
 cell proliferation and CD4⁺ T cell exhaustion and the role of these factors in the
 pathophysiology of PTLD.

Mechanistically, human NFAT1 deficiency has revealed the remarkable pleiotropic and 666 cell-type specific functions of NFAT1. Our study supports previous work that ascribed 667 both oncogenic and tumor suppressor roles to NFAT1, depending on the cell type²⁴. 668 Informed by this patient, NFAT1 serves as a tumor suppressor in chondrocytes and B 669 cells. This work also clarifies the role of human NFAT1 in B cell class-switching. 670 Specifically, the B cell differentiation block is likely attributable to impaired T cell help. 671 Previous studies demonstrated that both NFAT1 and NFAT2 are important for T_{FH} 672 differentiation¹⁵. However, this NFAT1-deficient patient demonstrates that human 673 NFAT1 is likely dispensable for T_{FH} differentiation but is critical for T_{FH} activation and 674 function (Fig. 6B-I). Similarly, NFAT1 is essential for T_H cell differentiation and cytokine 675 production (**Fig. 5F-5N**). One possible explanation for impaired CD4⁺ memory function 676 could be that they are exhausted. This is supported by high PD-1 (Fig. 6A), and TIGIT 677 (Fig. 5A-5B) expression⁷⁴. 678

Accumulation of memory T cells^{34, 75}, along with hyperresponsiveness has been 679 documented in T cells of *Nfatc2^{-/-}* mice^{64, 65, 75, 76}. We observed suppressed cytokine 680 signaling in the patient memory CD4⁺ and CD8⁺ cells. However, patient naïve CD4⁺ T 681 cells do display signatures of activation, with higher PD-1 and CD69 (Supp. Fig. 2J – 682 **2T**), as well as higher expression of T cell activation markers $CXCR3^{\prime\prime}$, *ITGA4* (an α 683 subunit of integrin receptors), and *IL2RB* (CD122) (Supp. Table 3), a cytokine receptor 684 recently found to be involved in homeostatic proliferation of naïve CD4⁺ T cells⁷⁸. Higher 685 686 activation status in naïve T cells might explain the age-associated accumulation of memory T cells observed in knock-out mice³⁴ and the NFAT1-deficient patient. 687

Given the significant T and B cell dysregulation identified in this NFAT1-deficient patient and the absence of classical features for immunodeficiency (recurrent/severe/unusual infections), we propose to classify human NFAT1 deficiency as a primary immune regulatory disorder⁷⁹. Studying this first reported patient has given us unique insight into the role of NFAT1 in the human musculoskeletal and immune systems. Our findings

- 693 corroborate decades of *Nfatc2^{-/-}* murine studies, while also providing a mechanistic
- ⁶⁹⁴ understanding of human NFAT1 deficiency in different cell types. Beyond individual
- patients, this study also informs the clinical implementation of calcineurin inhibitors and
- highlights potential adverse consequences of long-term use.

Table 1: Major Clinical Features. Patient clinical features organized by

- 699 musculoskeletal or immunological/hematological abnormalities.

Musculoskeletal	Immunological/Hematological
Contractures of upper limb joints, hips, knees, ankles	B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and cHL
Mobility issues: stiff gait, decreased stride length, toe walking	Widespread lymphadenopathy: abdominal, inguinal, hepatic, splenic, paratracheal, subcarinal, bone. No bone marrow involvement.
Decreased arm swing and knee range of motion. Anterior pelvic tilt with adduction of thighs	Lymph node tissue demonstrates malignant, large, mono- or binucleated cells within a benign background inflammatory cell infiltrate composed of small lymphocytes, eosinophils, histiocytes, and neutrophils
Ill-defined sclerotic bands present in the metaphyses of both the femoral tibia and fibula	Lymph node: effaced/abnormal architecture, large atypical CD79a ⁺ CD30 ⁺ CD20 ⁺ CD15 ⁻ PAX5 ⁺ B cells, positive BCL6 rearrangement, negative BCL2 rearrangement
Presence of multiple small pedunculated osteochondromas	
Developed severe spinal cord stenosis at level C3 C4, requiring posterior cervical decompression and fusion	
Bone Density Scan (DEXA): <u>Lumbar spine L1-4</u> : 0.739 (g/cm ²); Z-Score for chronologic age: -1.4; Z-score corrected for height: +0.2 <u>Total left hip</u> : 0.865 (g/cm ²); Z-Score for chronological age 1.0; Z-score corrected for height: +0.2 <u>Total body</u> : 0.888 (g/cm ²); Z-Score for chronologic age: -1.9; Z-score corrected for height: -0.4	
No evidence of muscle necrosis or regeneration, no increased endomysia fibrous tissue, no inflammation, no atypical cells	

Table 2: Comparison of human NFAT1 deficiency, Nfatc2-/- mice, and patients on calcineurin inhibitors.

	NFAT1 deficient patient	<i>Nfatc2^{-/-}</i> KO mice	Use of calcineurin inhibitors
Skeletal abnormalities and cartilage/ chondrocyte	Joint contractures, difficulty in ambulation. decreased range of motion in joints.	Joint contractures, difficulty in ambulation. decreased range of motion in joints ¹⁸ .	
defects	Increased cell cycling, resistance to apoptosis in osteochondroma chondrocytes	Invasive cartilage cells <i>in</i> <i>vivo</i> and contact-induced growth inhibition in <i>vitro</i> , Chondrosarcoma ¹⁸ .	Proliferation of chondrocytes from articular cartilage ⁸⁰ .
	Increased <i>MMP9</i> and increased IL6/IL-6- STAT3 pathway in patient chondrocytes	Susceptible to osteoarthritis, increased catabolic and decreased anabolic activity in articular cartilage, increased <i>IL6</i> ²⁰ .	
	Low total body bone mineral density with vertebral compression fractures	Decreased bone volume ¹⁹ .	Posttransplant osteoporosis in organ recipients ⁶⁶ , reduced bone mass and osteoporosis in FK506-treated mice in mice ¹⁹ and rats ⁸¹ .
B cell lymphoma and malignancies	Effaced lymph node architecture, showing B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and cHL	Effaced lymph node architecture, increased incidence of B cell malignancies, features of anaplastic and/or plasmablastic plasmacytomas, and none in <i>Nfatc2</i> ⁺ / ³⁴ .	Post-transplant lymphoproliferative disorder (PTLD) mostly in EBV ⁺ B cells ^{82, 83} , anti- apoptotic effects in Burkitt's lymphoma cell line ⁸⁴ , increased incidence of lymphoma with topical calcineurin inhibitors ^{85, 86} .
CD4 ⁺ T cells impairments	Higher activated (CD69 ⁺) T cells, accumulation of CD4 ⁺ central memory that exhibit high PD-1 expression	Age-related increase in accumulation of activated CD69 ⁺ T cells and memory T cells in secondary lymphoid organs ³⁴ .	Increase in CD4 ⁺ T cell exhaustion post-kidney and post-liver transplants but not CD8 ^{+87, 88, 89} .
T follicular helper cell impairment	T_{FH} cells activation is impaired and there is a lack of B cell class switching.	<i>Nfatc1/Nfatc2</i> double knockout mice: impaired T_{FH} differentiation and function, impaired GC formation ¹⁵ .	Decreased T_{FH} numbers and function, low T_{FH} - mediated B cell differentiation in transplant patients ^{90, 91} .

708

709

711 **REFERENCES**

712	1.	Vig, M. & Kinet, J.P. Calcium signaling in immune cells. Nat Immunol 10, 21-27 (2009).
713 714 715	2.	Vaeth, M., Kahlfuss, S. & Feske, S. CRAC Channels and Calcium Signaling in T Cell-Mediated Immunity. <i>Trends Immunol</i> 41 , 878-901 (2020).
716 717 718	3.	Feske, S. Calcium signalling in lymphocyte activation and disease. <i>Nat Rev Immunol</i> 7 , 690-702 (2007).
719 720 721	4.	Vaeth, M. & Feske, S. NFAT control of immune function: New Frontiers for an Abiding Trooper. <i>F1000Res</i> 7 , 260 (2018).
722 723 724	5.	Macian, F. NFAT proteins: key regulators of T-cell development and function. <i>Nat Rev Immunol</i> 5 , 472-484 (2005).
725 726 727	6.	Loh, C. <i>et al.</i> Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. <i>J Biol Chem</i> 271 , 10884-10891 (1996).
728 729 730	7.	Luo, C. <i>et al.</i> Recombinant NFAT1 (NFATp) is regulated by calcineurin in T cells and mediates transcription of several cytokine genes. <i>Mol Cell Biol</i> 16 , 3955-3966 (1996).
731 732 733	8.	Luo, C. <i>et al.</i> Interaction of calcineurin with a domain of the transcription factor NFAT1 that controls nuclear import. <i>Proc Natl Acad Sci U S A</i> 93 , 8907-8912 (1996).
734 735 736	9.	Shaw, K.T. <i>et al.</i> Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. <i>Proc Natl Acad Sci U S A</i> 92 , 11205-11209 (1995).
737 738 739	10.	Clipstone, N.A. & Crabtree, G.R. Identification of calcineurin as a key signalling enzyme in T- lymphocyte activation. <i>Nature</i> 357 , 695-697 (1992).
740 741 742	11.	Rao, A., Luo, C. & Hogan, P.G. Transcription factors of the NFAT family: regulation and function. <i>Annu Rev Immunol</i> 15 , 707-747 (1997).
743 744 745	12.	Shibasaki, F., Price, E.R., Milan, D. & McKeon, F. Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4. <i>Nature</i> 382 , 370-373 (1996).
746 747 748	13.	Shaw, J.P. <i>et al.</i> Identification of a putative regulator of early T cell activation genes. <i>Science</i> 241 , 202-205 (1988).
749		

750 751	14.	Hermann-Kleiter, N. & Baier, G. NFAT pulls the strings during CD4+ T helper cell effector functions. <i>Blood</i> 115 , 2989-2997 (2010).
752 753 754	15.	Martinez, G.J. <i>et al.</i> Cutting Edge: NFAT Transcription Factors Promote the Generation of Follicular Helper T Cells in Response to Acute Viral Infection. <i>J Immunol</i> 196 , 2015-2019 (2016).
755 756 757	16.	Peng, S.L., Gerth, A.J., Ranger, A.M. & Glimcher, L.H. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. <i>Immunity</i> 14 , 13-20 (2001).
758 759 760	17.	Zanoni, I. <i>et al.</i> CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. <i>Nature 460, 264-268 (2009).</i>
761 762 763	18.	Ranger, A.M. <i>et al.</i> The nuclear factor of activated T cells (NFAT) transcription factor NFATp (NFATc2) is a repressor of chondrogenesis. <i>J Exp Med</i> 191 , 9-22 (2000).
764 765 766	19.	Koga, T. <i>et al.</i> NFAT and Osterix cooperatively regulate bone formation. <i>Nat Med</i> 11 , 880-885 (2005).
767 768 769	20.	Wang, J. <i>et al.</i> Transcription factor Nfat1 deficiency causes osteoarthritis through dysfunction of adult articular chondrocytes. <i>J Pathol</i> 219 , 163-172 (2009).
770 771 772 773	21.	Ho, I.C., Kim, J.H., Rooney, J.W., Spiegelman, B.M. & Glimcher, L.H. A potential role for the nuclear factor of activated T cells family of transcriptional regulatory proteins in adipogenesis. <i>Proc Natl Acad Sci U S A</i> 95 , 15537-15541 (1998).
774 775 776	22.	Bourajjaj, M. <i>et al.</i> NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. <i>J Biol Chem</i> 283 , 22295-22303 (2008).
777 778 779	23.	Jauliac, S. <i>et al.</i> The role of NFAT transcription factors in integrin-mediated carcinoma invasion. <i>Nat Cell Biol</i> 4 , 540-544 (2002).
780 781 782 783	24.	Mognol, G.P., Carneiro, F.R., Robbs, B.K., Faget, D.V. & Viola, J.P. Cell cycle and apoptosis regulation by NFAT transcription factors: new roles for an old player. <i>Cell Death Dis</i> 7 , e2199 (2016).
784 785 786 787	25.	Casolaro, V. <i>et al.</i> Inhibition of NF-AT-dependent transcription by NF-kappa B: implications for differential gene expression in T helper cell subsets. <i>Proc Natl Acad Sci U S A</i> 92 , 11623-11627 (1995).
788 789 790	26.	Liu, J. <i>et al.</i> Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. <i>Cell</i> 66 , 807-815 (1991).

704		
791 792	27.	First, M.R. Tacrolimus based immunosuppression. J Nephrol 17 Suppl 8 , S25-31 (2004).
793 794 795	28.	Azzi, J.R., Sayegh, M.H. & Mallat, S.G. Calcineurin inhibitors: 40 years later, can't live without. <i>J</i> Immunol 191 , 5785-5791 (2013).
796 797 798	29.	Cury Martins, J. <i>et al.</i> Topical tacrolimus for atopic dermatitis. <i>Cochrane Database Syst Rev,</i> CD009864 (2015).
799 800	30.	Safarini, O.A. & Patel, J. Calcineurin Inhibitors. <i>StatPearls</i> : Treasure Island (FL), 2021.
801 802 803	31.	Lee, M. & Park, J. Regulation of NFAT activation: a potential therapeutic target for immunosuppression. <i>Mol Cells</i> 22 , 1-7 (2006).
804 805 806	32.	van Kuilenburg, A.B.P. <i>et al</i> . Glutaminase Deficiency Caused by Short Tandem Repeat Expansion in GLS. <i>N Engl J Med</i> 380 , 1433-1441 (2019).
807 808 809	33.	Tarailo-Graovac, M. <i>et al.</i> Exome Sequencing and the Management of Neurometabolic Disorders. <i>N Engl J Med</i> 374 , 2246-2255 (2016).
810 811 812	34.	May, S.L. <i>et al.</i> Nfatc2 and Tob1 have non-overlapping function in T cell negative regulation and tumorigenesis. <i>PLoS One</i> 9 , e100629 (2014).
813 814 815	35.	Lu, H.Y. <i>et al.</i> Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency. <i>J Allergy Clin Immunol</i> (2021).
816 817 818	36.	Lu, H.Y. <i>et al.</i> The importance of functional validation after next-generation sequencing: evaluation of a novel CARD11 variant. <i>Pediatr Allergy Immunol</i> 29 , 663-668 (2018).
819 820 821	37.	Fung, S.Y. <i>et al.</i> MALT1-Dependent Cleavage of HOIL1 Modulates Canonical NF-kappaB Signaling and Inflammatory Responsiveness. <i>Front Immunol</i> 12 , 749794 (2021).
822 823 824	38.	Kutner, R.H., Zhang, X.Y. & Reiser, J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. <i>Nat Protoc</i> 4 , 495-505 (2009).
825 826 827	39.	Jia, A. <i>et al.</i> Clinical IRAK4 deficiency caused by homozygosity for the novel IRAK4 (c.1049delG, p.Gly350Glufs*15) variant. <i>Cold Spring Harb Mol Case Stud</i> 6 (2020).
828 829 830	40.	Carson, R.T. & Vignali, D.A. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. <i>J Immunol Methods</i> 227 , 41-52 (1999).

831 832 833	41.	Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. <i>Methods</i> 25 , 402-408 (2001).
834 835 836 837	42.	Chen, Y., Lun, A.T. & Smyth, G.K. From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. <i>F1000Res</i> 5 , 1438 (2016).
838 839 840	43.	Ritchie, M.E. <i>et al.</i> limma powers differential expression analyses for RNA-sequencing and microarray studies. <i>Nucleic Acids Res</i> 43 , e47 (2015).
841 842 843	44.	Kulpa, D.A. <i>et al.</i> Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4(+) T Cells. <i>J Virol</i> 93 (2019).
844 845 846	45.	Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. <i>Nat Biotechnol</i> 36 , 411-420 (2018).
847 848 849	46.	Aran, D. <i>et al.</i> Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. <i>Nat Immunol</i> 20 , 163-172 (2019).
850 851 852	47.	Novershtern, N. <i>et al.</i> Densely interconnected transcriptional circuits control cell states in human hematopoiesis. <i>Cell</i> 144 , 296-309 (2011).
853 854 855	48.	Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. <i>Genome Biol</i> 20 , 296 (2019).
856 857 858	49.	Robinson, M.D. & Smyth, G.K. Moderated statistical tests for assessing differences in tag abundance. <i>Bioinformatics</i> 23 , 2881-2887 (2007).
859 860 861	50.	Burrage, P.S., Mix, K.S. & Brinckerhoff, C.E. Matrix metalloproteinases: role in arthritis. <i>Front</i> <i>Biosci</i> 11 , 529-543 (2006).
862 863 864	51.	Nguyen, L., Papenhausen, P. & Shao, H. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects. <i>Genes (Basel)</i> 8 (2017).
865 866 867	52.	McGettrick, A.F. & O'Neill, L.A.J. The Role of HIF in Immunity and Inflammation. <i>Cell Metab</i> 32 , 524-536 (2020).
868 869 870	53.	Zhu, F., Wang, K.B. & Rui, L. STAT3 Activation and Oncogenesis in Lymphoma. <i>Cancers (Basel)</i> 12 (2019).


871 872 873	54.	Zhang, Y. <i>et al.</i> Tumor necrosis factor-alpha induced protein 8 polymorphism and risk of non- Hodgkin's lymphoma in a Chinese population: a case-control study. <i>PLoS One</i> 7 , e37846 (2012).
874 875 876	55.	Corso, J. <i>et al.</i> Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival. <i>Proc Natl Acad Sci U S A</i> 113 , 5688-5693 (2016).
877 878 879	56.	Jasenosky, L.D. <i>et al.</i> Identification of a Distal Locus Enhancer Element That Controls Cell Type- Specific TNF and LTA Gene Expression in Human T Cells. <i>J Immunol</i> 205 , 2479-2488 (2020).
880 881 882	57.	Kuprash, D.V. <i>et al.</i> Cyclosporin A blocks the expression of lymphotoxin alpha, but not lymphotoxin beta, in human peripheral blood mononuclear cells. <i>Blood</i> 100 , 1721-1727 (2002).
883 884 885	58.	Xu, T., Keller, A. & Martinez, G.J. NFAT1 and NFAT2 Differentially Regulate CTL Differentiation Upon Acute Viral Infection. <i>Front Immunol</i> 10 , 184 (2019).
886 887 888	59.	Vafadari, R., Kraaijeveld, R., Weimar, W. & Baan, C.C. Tacrolimus inhibits NF-kappaB activation in peripheral human T cells. <i>PLoS One</i> 8 , e60784 (2013).
889 890 891 892	60.	Nassef Kadry Naguib Roufaiel, M., Wells, J.W. & Steptoe, R.J. Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse? <i>Front Immunol</i> 6 , 258 (2015).
893 894 895	61.	Shin, D.S. <i>et al.</i> Regulatory T cells suppress CD4+ T cells through NFAT-dependent transcriptional mechanisms. <i>EMBO Rep</i> 15 , 991-999 (2014).
896 897 898 899	62.	Ding, B.B., Bi, E., Chen, H., Yu, J.J. & Ye, B.H. IL-21 and CD40L synergistically promote plasma cell differentiation through upregulation of Blimp-1 in human B cells. <i>J Immunol</i> 190 , 1827-1836 (2013).
900 901 902	63.	Bauer, W. <i>et al.</i> Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2. <i>Haematologica</i> 96 , 1580-1588 (2011).
903 904 905	64.	Xanthoudakis, S. <i>et al.</i> An enhanced immune response in mice lacking the transcription factor NFAT1. <i>Science</i> 272 , 892-895 (1996).
906 907 908	65.	Hodge, M.R. <i>et al.</i> Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient mice. <i>Immunity</i> 4 , 397-405 (1996).
909 910 911	66.	Yu, T.M. <i>et al.</i> Osteoporosis and fractures after solid organ transplantation: a nationwide population-based cohort study. <i>Mayo Clin Proc</i> 89 , 888-895 (2014).

912 913 914	67.	Teixeira, L.K. <i>et al.</i> NFAT1 transcription factor regulates cell cycle progression and cyclin E expression in B lymphocytes. <i>Cell Cycle</i> 15 , 2346-2359 (2016).
915 916 917	68.	Schmid, C.A. <i>et al.</i> DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma. <i>J Exp Med</i> 212 , 775-792 (2015).
918 919 920	69.	Xu-Monette, Z.Y., Zhou, J. & Young, K.H. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. <i>Blood</i> 131 , 68-83 (2018).
921 922 923	70.	Rosales, Y.M.Z. <i>et al.</i> Use of checkpoint inhibitors in gray zone lymphoma. <i>Hematol Oncol Stem</i> <i>Cell Ther</i> (2020).
924 925 926 927	71.	Al-Mansour, Z., Nelson, B.P. & Evens, A.M. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. <i>Curr Hematol Malig Rep</i> 8 , 173-183 (2013).
928 929 930	72.	Singavi, A.K., Harrington, A.M. & Fenske, T.S. Post-transplant lymphoproliferative disorders. <i>Cancer Treat Res</i> 165 , 305-327 (2015).
931 932 933	73.	Rengarajan, J. <i>et al.</i> Sequential involvement of NFAT and Egr transcription factors in FasL regulation. <i>Immunity</i> 12 , 293-300 (2000).
934 935 936	74.	Miggelbrink, A.M. <i>et al.</i> CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer? <i>Clin Cancer Res</i> 27 , 5742-5752 (2021).
937 938 939	75.	Karwot, R. <i>et al.</i> Protective role of nuclear factor of activated T cells 2 in CD8+ long-lived memory T cells in an allergy model. <i>J Allergy Clin Immunol</i> 121 , 992-999 e996 (2008).
940 941 942	76.	Kwon, H.K. <i>et al.</i> Transcription factor NFAT1 controls allergic contact hypersensitivity through regulation of activation induced cell death program. <i>Sci Rep</i> 6 , 19453 (2016).
943 944 945	77.	Kuo, P.T. <i>et al.</i> The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer. <i>Front</i> <i>Med (Lausanne)</i> 5 , 271 (2018).
946 947 948 949	78.	Keller, H.R. <i>et al.</i> The Abundance and Availability of Cytokine Receptor IL-2Rbeta (CD122) Constrain the Lymphopenia-Induced Homeostatic Proliferation of Naive CD4 T Cells. <i>J Immunol</i> 204 , 3227-3235 (2020).
950 951 952	79.	Chan, A.Y. & Torgerson, T.R. Primary immune regulatory disorders: a growing universe of immune dysregulation. <i>Curr Opin Allergy Clin Immunol</i> 20 , 582-590 (2020).

953 954 955 956	80.	Kang, S.W., Kim, J. & Shin, D.Y. Inhibition of senescence and promotion of the proliferation of chondrocytes from articular cartilage by CsA and FK506 involves inhibition of p38MAPK. <i>Mech Ageing Dev</i> 153 , 7-13 (2016).
957 958 959	81.	Kirino, S. <i>et al.</i> Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. <i>J</i> Bone Miner Metab 22 , 554-560 (2004).
960 961 962	82.	Caduff, N. <i>et al.</i> Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. <i>PLoS Pathog</i> 16 , e1008477 (2020).
963 964 965	83.	Taylor, A.L., Marcus, R. & Bradley, J.A. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. <i>Crit Rev Oncol Hematol</i> 56 , 155-167 (2005).
966 967 968	84.	Kondo, E. <i>et al.</i> NF-ATc2 induces apoptosis in Burkitt's lymphoma cells through signaling via the B cell antigen receptor. <i>Eur J Immunol</i> 33 , 1-11 (2003).
969 970 971 972	85.	Lam, M., Zhu, J.W., Tadrous, M. & Drucker, A.M. Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis. <i>JAMA Dermatol</i> 157 , 549-558 (2021).
973 974 975	86.	Wu, P.C., Huang, I.H., Liu, C.W. & Huang, Y.C. Topical calcineurin inhibitors and risk of lymphoma: a systematic review and meta-analysis. <i>J Dtsch Dermatol Ges</i> 19 , 1265-1269 (2021).
976 977 978	87.	Angeletti, A., Cantarelli, C., Riella, L.V., Fribourg, M. & Cravedi, P. T Cell Exhaustion in Organ Transplantation. <i>Transplantation</i> (2021).
979 980 981	88.	Fribourg, M. <i>et al.</i> T-cell exhaustion correlates with improved outcomes in kidney transplant recipients. <i>Kidney Int</i> 96 , 436-449 (2019).
982 983 984	89.	Li, J. <i>et al.</i> Regulatory effect of FK506 on CD152 and PD-1 in the liver allorecipients. <i>Transplant</i> <i>Proc</i> 40 , 1495-1497 (2008).
985 986 987	90.	Zhang, K. <i>et al.</i> A pilot study on the characteristics of circulating T follicular helper cells in liver transplant recipients. <i>Transpl Immunol</i> 47 , 32-36 (2018).
988 989 990	91.	Wallin, E.F., Hill, D.L., Linterman, M.A. & Wood, K.J. The Calcineurin Inhibitor Tacrolimus Specifically Suppresses Human T Follicular Helper Cells. <i>Front Immunol</i> 9 , 1184 (2018).
991		
992		

993


994 **Figures:**



996 Fig. 1. Clinical phenotype of a patient with NFAT1 deficiency, joint contractures,

997 and B cell malignancy. A) X-ray demonstrating extent to which knees could be

- straightened documenting the fixed flexion deformity. **B)** Osteochondroma (indicated by
- the arrow) on the anterior aspect of the right proximal fibula. **C)** Hematoxylin and eosin
- 1000 (H&E) stain, and CD20, CD21, CD30, BCL2, and BCL6 immunostain of a patient lymph
- node biopsy. Scale bar for H&E, CD20, CD30, BCL6, and BCL2 is 50µm and for CD21
- is 3mm. D) Family pedigree. Half-filled symbols=heterozygous unaffected individuals,
- 1003 filled symbols=homozygous affected individual, arrow=proband, question
- 1004 marks=ungenotyped. E) Sanger sequencing of DNA extracted from whole blood of the
- 1005 patient, family members, and a healthy control. Site of four base pair deletion is
- indicated. F) Schematic illustrating the protein domains of NFAT1. Location of variant
- shown in red. Affected region was aligned to other species. Asterisks indicate full
- 1008 conservation. **G)** Schematic illustrating ionomycin-induced activation of calcineurin and
- 1009 NFAT1. **H)** *NFATC2* transcript abundance relative to β -actin (*ACTB*) in the patient (II-1),
- 1010 a heterozygous control (II-2), and a healthy control (HC) determined by qPCR. Red
- circles=II-1, blue circles=II-2, green circles=HC. ** p<0.01, ****p<0.0001. One-way
- 1012 ANOVA and Tukey's post-hoc test. I) Immunoblot of patient (II-1), heterozygous control
- 1013 (II-2), and control-derived LCLs using an N-terminal NFAT1 antibody before and after
- 1014 10 min ionomycin stimulation with or without FK506 treatment. N = 3.



1017 Fig. 2. NFAT1 deficiency in chondrocytes leads to an increased pro-survival and

- 1018 proinflammatory phenotype. A) Immunoblot of empty vector (EV)- and WT NFATC2-
- transduced patient chondrocytes before and after 15min phorbol 12-myristate 13-
- acetate/ionomycin (P/I) stimulation, 20ng/mL IL-1β stimulation, or no treatment. n=3. B-
- **D)** RNA-Seq carried out on EV- or WT *NFATC2*-transduced patient chondrocytes
- unstimulated or stimulated 24h with P/I or 20ng/mL IL-1β. B) Venn diagram of
- significantly (FDR<0.05) (i) upregulated and (ii) downregulated genes in EV-transduced
- 1024 patient chondrocytes compared to WT *NFATC2*-transduced chondrocytes. **C)** Heatmap
- 1025 of top genes that meet a FDR<0.025 cutoff between EV and WT *NFATC2*-transduced
- patient chondrocytes. **D)** Heatmap of sample level enrichment scores (SLEA) scores
- 1027 with normalized enrichment scores (NES), p-val, and q-values for each pathway
- determined by gene set enrichment analysis (GSEA). Min and max refer to the row-
- normalized minimum and maximum for each pathway. E) Measurement of percent cell
- 1030 death in chondrocytes over 12 days by quantifying lactate dehydrogenase in
- 1031 supernatants. *p<0.05, ***p<0.001 Two-way ANOVA, Dunnett's post-hoc test. F) ELISA
- 1032 detection of IL-6 production from the supernatants of chondrocytes in different
- 1033 conditions. *p<0.05, ***p<0.001 Mann-Whitney U-test.





Fig. 3. NFAT1 deficiency leads to accumulation of hyperproliferative naïve B cells. A-C) Single cell RNA-1035 Sequencing of peripheral blood mononuclear cells from the patient (II-1), heterozygous controls (n=3), and a healthy 1036 control (n=2) stimulated with P/I for 4h. A) Uniform manifold approximation and projection (UMAP) visualization of 1037 stimulated cell subsets. Cell labels indicated on right. B) Volcano plot showing differential gene expression in naïve B cells 1038 between patient and 5 healthy controls. Dark colors=significance, dim colors=nominal significance but not after adjusted 1039 p-value, grey colors=not significant. C) Violin plots of significantly differentially expressed genes of interest in naïve B cells 1040 comparing patient and healthy controls. D) Expression of NFAT1 in patient and control naïve B cells. Mean fluorescence 1041 intensities (MFIs) are indicated. E) Frequency of IgM⁺⁺CD38⁺⁺ transitional B cells in the patient (II-1) and heterozygous 1042 (n=4) and healthy controls (n=8). F) Quantification of E). G) Frequency of IgD⁺CD27⁻ naïve (N) and IgD⁻CD27⁺ memory 1043 (M) B cells in the patient and one representative control. Schematic of guadrants that correspond to each cell population 1044 and frequency shown top right. H,I) Quantification of G). J) Frequency of CD27⁺CD38⁺ plasmablasts in mature CD19⁺ B 1045 cells. K) IgD and IgM expression in each individual. MFIs are indicated. I) Frequency of Ki67⁺ naïve B cells in the patient 1046 and a representative control. M) Quantification of I). N) Frequency of TNF- α^+ naïve B cells in the patient and a 1047 representative control. O) Quantification of n). P-Q) Isolated naïve B cells from patient, heterozygous (n=1), and healthy 1048 controls (n=6) expanded for 6 days. P) Frequency of class-switched memory B cells and Q) plasmablasts before and after 1049 expansion. *p<0.05, **p<0.01. One-way ANOVA and Tukey's posthoc test. Green circles=healthy control, blue circle=II-2, 1050 blue upright triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1. 1051



1053	Fig. 4. NFAT1 deficiency impairs memory CD8 ⁺ T cell function. A) Volcano plot
1054	showing differential gene expression in $CD8^+$ memory T cells between patient and 5
1055	healthy controls (3 heterozygous controls, and 2 healthy controls). B) Violin plots of
1056	significantly differentially expressed genes of interest in $CD8^+$ memory T cells in patient
1057	and healthy controls. C) Frequency of CD8 ⁺ T cell subsets in the patient and a
1058	representative control, including CD45RA ⁺ CD27 ⁻ TEMRA, CD45RA ⁺ CD27 ⁺ Naïve (N),
1059	CD45RA ⁻ CD27 ⁻ effector memory (EM), CD45RA ⁻ CD27 ⁺ central memory (CM).
1060	Quadrants corresponding to each subset shown top right. D) Quantification of C). E)
1061	Expression of NFAT1 in patient and control naïve and memory $CD8^+ T$ cells. Mean
1062	fluorescence intensities (MFIs) are indicated. F) TNF- α and IFN- γ expression in memory
1063	CD8 ⁺ T cells in the patient and a control. G, H) Quantification of F) . I) CD69 and PD-1
1064	expression in patient and control memory $CD8^+$ T cells after 4h of P/I stimulation. MFIs
1065	are indicated. *p<0.05, ****p<0.0001. One-way ANOVA and Tukey's post-hoc test.
1066	Green circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted
1067	triangle=I-1, blue square=II-3, red diamond=II-1.
1068	
1069	
1070	
1071	
1072	
1073	
1074	
1075	
1076	
1077	
10//	




Fig. 5. Patient CD4⁺ T cells are exhausted. A) Volcano plot showing differential gene expression in CD4⁺ memory T 1079 cells between patient and 5 healthy controls. B) Violin plots of significantly differentially expressed genes of interest in 1080 CD4⁺ memory T cells in patient and healthy controls. C) Frequency of CD8⁺ T cell subsets in the patient and a 1081 representative control, including CD45RA⁺CD27⁻ TEMRA, CD45RA⁺CD27⁺ Naïve (N), CD45RA⁻CD27⁻ effector memory 1082 (EM), CD45RA⁻CD27⁺ central memory (CM). Quadrants corresponding to each subset shown top right. D) Quantification 1083 of C). E) Expression of NFAT1 in patient and control naïve and memory CD4⁺ T cells. Mean fluorescence intensities are 1084 indicated. F) Frequency of T_{H1} (IFN-y⁺IL-17A⁻), T_{H17} (IL-17A⁺IFN-y⁺) cells in memory CD4⁺ T cells of the patient and a 1085 representative control. **G-H)** Quantification of **F)**. **I)** Frequency of T_H2 (IL-4⁺IL-21⁻) and T_{FH} (IL-21⁺IL-4⁻) cells in memory 1086 CD4⁺ T cells of the patient and a representative control. J-K) Quantification of I). L) Frequency of TNF- α^+ and IL-2⁺ CD4⁺ 1087 memory T cells in the patient and a representative control. **M**,**N**) Quantification of **L**). *p<0.05, **p<0.01, ***p<0.001, 1088 ****p<0.0001. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy control, blue circle=II-2, blue upright 1089 triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1. 1090






Fig. 6. NFAT1 deficiency impairs T_{FH} function. A) Expression of activation markers in 1092 CD4⁺ memory T cells after P/I treatment, including CD69, PD-1, CD40L, CD25 and 1093 1094 ICOS. Mean fluorescence intensities (MFIs) are indicated. B) Frequency of circulating T_{FH} (cT_{FH}) cells in PD-1⁺ memory CD4⁺ T cells in the patient and a representative 1095 1096 control. C) Quantification of B). D) CD40L and IL-21 expression in patient and control cT_{FH} cells after 4h P/I stimulation. **E.F)** Quantification of **D**). **G**) Frequency of CD40L⁺ 1097 and TNF-a⁺ GFP⁺ CD4⁺ patient or control memory T cells after 4h P/I stimulation of EV 1098 or WT NFATC2 transduction. H,I) Quantification of G). *p<0.05, **p<0.01, ***p<0.001, 1099 ****p<0.0001. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy 1100

- 1101 control, blue circle=II-2, blue upright triangle=I-2, blue inverted triangle=I-1, blue
- square=II-3, red diamond=II-1.


Supplementary figures:




Supp Fig. 1. Extended B cell phenotyping. **A)** Gating strategy for transitional B cells and plasmablasts in mature CD19⁺ B cells. **B,C)** Quantification of IgD and IgM MFI in patient and control naïve B cells. **D)** Naïve B cells were isolated from patient and a control and expanded *in vitro*. Frequency of CD27⁺CD38⁻ memory B cells was enumerated at Day 0 (Non-expanded) and Day 6 (Expanded). **p<0.01. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted triangle=I-1, blue square=II-3, red diamond=II-1.




Supp Fig. 2. Extended CD8+ T cell phenotyping. A) Frequency of IL-2⁺ naïve CD8⁺ T 1115 cells in the patient and a representative control. B) Quantification of A). C) Frequency of 1116 IL-2⁺ memory CD8⁺ T cells in the patient and a representative control. **D)** Quantification 1117 of C). E) CD40L expression in memory CD8⁺ T cells. Mean fluorescence intensities are 1118 indicated. F-H) Quantification of F) CD40L⁺, G) CD69⁺, and H) PD-1⁺ CD8⁺ memory T 1119 cells. *p<0.05, **p<0.01. One-way ANOVA and Tukey's post-hoc test. Green 1120 circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted 1121 1122 triangle=I-1, blue square=II-3, red diamond=II-1.



Supp Fig. 3. Extended CD4⁺ T cell immunophenotyping. A) Frequency of IFN-y⁺ and IL-17A⁺ naïve CD4⁺ T cells in the 1124 patient and a representative control. B,C) Quantification of A). D) Frequency of IL-21⁺ and IL-4⁺ naïve CD4⁺ T cells in the 1125 patient and a representative control. E,F) Quantification of D). G) Frequency of TNF- α^+ and IL-2⁺ naïve CD4⁺ T cells in the 1126 patient and a representative control. H,I) Quantification of G). J) naïve CD4⁺ T cell expression of activation markers, 1127 including PD-1, CD40L, CD69, CD25, and ICOS. Mean fluorescence intensities (MFIs) are indicated. K-O) Frequency of 1128 same activation markers as in J). P-T) Quantification of frequencies and MFIs of CD4⁺ memory T cell activation markers, 1129 including PD-1, CD40L, CD69, CD25 and ICOS. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. One-way ANOVA and 1130 Tukey's post-hoc test. Green circles=healthy control, blue circle=II-2, blue upright triangle=I-2, blue inverted triangle=I-1, 1131 blue square=II-3, red diamond=II-1. 1132



Supp Fig. 4. CD4⁺ T cell gating strategies. A) Gating strategy for circulating T follicular helper cells (T_{FH}) defined as CD3⁺CD4⁺CD8⁻CD45RA⁻CXCR5⁺PD-1⁺. B) Gating strategy for identifying WT *NFATC2*-transduced CD4⁺ memory T cells.



Supp Fig. 5. Patient T regulatory cell phenotype. A) Gating strategy for naïve and activated T regulatory cells (Treg) defined as CD3⁺CD4⁺CD8⁻CD25⁺CD127⁻FOXP3⁺ and CD45RA^{+/-}. B,C) Frequency of B) naïve and C) memory Tregs. D) Frequency of TNF- α^+ and IFN- γ^+ activated Tregs in the patient and a representative control. E,F) Quantification of D). G) Frequency of IL-2⁺ activated Tregs in the patient and a representative control. H) Quantification of G). I-O) Quantification of Treg stability markers I) FOXP3 and J) Helios, and activation markers, K) CD25, L) CD69, M) CTLA4, N) ICOS, and O) PD-1 in activated Tregs. **p<0.01. One-way ANOVA and Tukey's post-hoc test. Green circles=healthy control, red diamond=II-1.

1145 **Supplementary Tables:**

1146

1147 **Supplementary Table 1:** Gait and physical assessment in the patient

	Gait Assessment	Physical Assessment	
	Anterior pelvic tilt with adduction of thighs	Hip flexion contractures bilaterally, - 20°	
	Decreased dynamic hip range of motion	Decreased hip abduction, 5° right, 10° left	
Hip	Decreased hip extension in terminal stance	Decreased hip external rotation, neutral bilaterally	
	Hip flexion contractures	Decreased hip internal rotation, 25° right, 10° left	
		Positive Thomas test bilaterally	
		Positive Ober test bilaterally	
	Knee flexion contractures bilaterally with decreased popliteal angles	Knee flexion contractures bilaterally, -45° right, -30° left	
Knee	Increased knee flexion throughout stance	Popliteal angles; -70° right, -50° left	
	Incomplete knee flexion throughout terminal swing	Total range of motion for his left knee is approximately 30 -40°, and total range of motion for his right knee is approximately 90°	
	Decreased ankle dorsiflexion bilaterally	Decreased ankle dorsiflexion bilaterally; -10° with knee flexed, - 20° with knee extended	
Ankle	Sagittal joint powers are decreased at the ankle, left more than right		
	Absent first rocker bilaterally with abbreviated left second ankle rocker and aborted right second ankle rockers		
	Neutral foot progression angle on the frontal plane		
Foot	Mild left hind foot varus with forefoot pronation		
	Bilateral forefoot internal rotation		
	Pedobarography shows absent hindfoot pressures bilaterally		
Upper limbs	Decreased arm swing	Very limited flexion and extension of both thumb MCPs and both wrists	
		limited extension, internal and	

		external rotation of his shoulders, as well as limited lateral flexion of the cervical spine
	Functional Mobility Scale (FMS), Ebrahim receives a score of 6 at 5 metres, 6 at 50 metres, and 6 at 500 metres	Demonstrates toe walking, worse on the right than on the left
Stride	Decreased step and stride lengths	When he gets from a sitting to standing position, he relies significantly on supports due to his contractures in his knees
	Mildly decreased velocity	
	Mild increased cadence	

1148

1149

1151 **Supplementary Table 2:** Clinical Flow Cytometry for determination of T cell and B cell

subset proportions in the patient along with reference intervals

	Patient Results		Age-Specific Reference Interval
Lymphocyte T and B Cell Panel		0	
CD3 Cells	1.51	10 ⁹ /L	0.70-2.10
CD3 ⁺ CD4 ⁺ Cells	0.74	10 ⁹ /L	0.30-1.40
CD3 ⁺ CD8 ⁺ Cells	0.70	10 ⁹ /L	0.20-0.90
CD4:CD8 Ratio	1.05		1.00-3.60
CD19 ⁺ Cells	0.14	10 ⁹ /L	0.10-0.50
CD3 ⁻ CD56 ⁺ Cells	0.10	10 ⁹ /L	
T-Cell Naïve & Memory & Effector (CD27 and CD45RA) Subsets Panel			
CD4 ⁺ Naïve T-Cells (CD45RA ⁺ CCR7 ⁺)	% of CD4⁺ T Cells	15.8	7.2-68.9
CD4 ⁺ Central Memory T-Cells (CD45RA ⁻ CCR7 ⁺)	% of CD4 ⁺ T Cells	69.9	15.0-64.3
CD4 ⁺ Effector Memory T-Cells (CD45RA ⁻ CCR7 ⁻)	% of CD4 ⁺ T Cells	13.6	4.9-43.6
CD4 ⁺ TEMRA T-Cells (CD45RA ⁺ CCR7 ⁻)	% of CD4 ⁺ T Cells	0.7	<11.7
CD4 ⁺ CD57 ⁺ Cells	% of CD4 ⁺ T Cells	0.9	0.6-30.4
CD4 ⁺ PD1 ⁺ Cells	% of CD4 ⁺ T Cells	64.8	1.7-21.5
CD8 ⁺ Naïve T-Cells (CD45RA ⁺ CCR7 ⁺)	% of CD8⁺ T Cells	20.5	2.6-72.4
CD8 ⁺ Central Memory T-Cells (CD45RA ⁻ CCR7 ⁺)	% of CD8⁺ T Cells	14.1	2.7-36.2
CD8 ⁺ Effector Memory T-Cells (CD45RA ⁻ CCR7 ⁻)	% of CD8⁺ T Cells	27.8	4.7-60.1

	% of CD8⁺ T	37.6	1.6-62.0
CD8 ⁺ TEMRA T-Cells (CD45RA ⁺ CCR7 ⁻)	Cells		
	% of CD8⁺ T	51.2	4.6-59.6
CD8 ⁺ CD57 ⁺ Cells	Cells		
	% of CD8⁺ T	20.8	5.2-63.4
CD8 ⁺ PD1 ⁺ Cells	Cells		
B-Cell Memory Subsets Panel			
Switched Memory B-Cells (CD27 ⁺ IgD ⁻ IgM-)	% of B Cells	0.2	4.6-35.5
Unswitched Memory B-Cells (CD27 ⁺ IgM ⁺)	% of B Cells	4.6	1.9-23.7
Naïve B-Cells (CD27⁻ IgD⁺)	% of B Cells	93.7	17.9-75.1
Transitional B-Cells (CD27 ⁻ IgM ⁺ CD24 ^{hi} CD38 ^{hi})	% of B Cells	15.7	0.1-6.3
CD21 ^{low} B Cells	% of B Cells	13.3	1.9-19.3

1153